{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:40:04Z","timestamp":1749638404616,"version":"3.41.0"},"reference-count":16,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15104","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:26:09Z","timestamp":1747826769000},"page":"1-5","source":"Crossref","is-referenced-by-count":0,"title":["Malignant mesothelioma with a novel <i>BAP1<\/i> germline frameshift mutation treated with dual immune checkpoint inhibitors: A case report"],"prefix":"10.3892","volume":"30","author":[{"given":"Na","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Yuan","sequence":"additional","affiliation":[{"name":"Geneplus\u2011Beijing, Beijing 102206, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuejuan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanwen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangni","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100005, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"key20250611125827_b1-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"key20250611125827_b2-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"key20250611125827_b3-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"key20250611125827_b4-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and Cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"key20250611125827_b5-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"e2405231121","DOI":"10.1073\/pnas.2405231121","article-title":"Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling","volume":"121","author":"Novelli","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20250611125827_b6-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jtho.2022.03.014","article-title":"Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations","volume":"17","author":"Carbone","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20250611125827_b7-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov"},{"key":"key20250611125827_b8-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/cncr.31908","article-title":"Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease","volume":"125","author":"Wu","year":"2019","journal-title":"Cancer"},{"key":"key20250611125827_b9-ol-30-1-15104","first-page":"850","article-title":"The mutation landscape of multiple cancer predisposition genes in Chinese familial\/hereditary breast cancer families","volume":"19","author":"Dong","year":"2021","journal-title":"Cancer Biol Med"},{"key":"key20250611125827_b10-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"737547","DOI":"10.3389\/fonc.2021.737547","article-title":"Germline mutation landscape and associated clinical characteristics in Chinese patients with renal cell carcinoma","volume":"11","author":"Kong","year":"2021","journal-title":"Front Oncol"},{"key":"key20250611125827_b11-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"key20250611125827_b12-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"key20250611125827_b13-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res"},{"key":"key20250611125827_b14-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: A phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"key20250611125827_b15-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: A validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20250611125827_b16-ol-30-1-15104","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","article-title":"Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma","volume":"27","author":"Oehl","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:58:35Z","timestamp":1749635915000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,21]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15104","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}